Interestingly, five of the 27 candidate genes identified above (ANO1, MEIS2, PDE4A, PMP22, and SRPX) were identified through pathway analysis as genes known to be downregulated in prostate cancer samples specifically, indicating the relevance of these candidates to PCa in other datasets as well. This evidence concerns the gene PMP22 and posterior cortical atrophy.